initi coverag
stock price
million per share
webcast
report limit sole use client wolf research pleas refer disclosur section locat end report
analyst certif disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research
initi alexion
outperform op rate pt
initi outperform rate pt pt impli upsid current
stock price ultim think trade depress level market price
ipr loss earli biosimilar entri key franchis dilig suggest
win ipr keep brand longer good soliris/ultomiri switch strategi help fend
addit bx competit given ultomiri price conveni rel current soc
think win on-going ipr soliri vs
keep franchis brand longer
consensu expect
lot good featur includ
next-gen ultomiri product help stave
bx competit price conveni
advantag soliri
continu signific yield trade
multipl line larg cap biotech
takeout make potenti target
lose ipr soliri
biosimilar enter market earli
fail switch meaning pt key
indic soliri ultomiri make
suscept competit threat
remain pipelin disappoint give
sourc includ limit pubm wolf research
alxn tough stock last
year differ
sourc includ limit pubm wolf research
said think alxn risk/reward
head late summer ipr decis
one best biotech
lose ipr
current price
us soliri sale
confid price
give
flexibl ultomiri
switch us
sourc includ limit pubm wolf research
want dig soliri ip case
click ipr webcast slide
present full analysi soliri ipr includ
sever crucial data point arent understood street
reason favor ipr
sourc includ limit pubm wolf research
get trade let acknowledg
alxn underperform recent
hasnt diversifi face
major busi
uncertainti price competit
consensu probabl model
competit legit
lot bad alreadi bake
pnh isnt big go forward
bake modest gmg growth
trade cheap
valuat vs takeout
soliris/ultomiri switch set
success
ultomiri advantag price
conveni
biosimilar adopt could limit
even bear case upsid
think mg hit
current level
comp analysi larg cap
ipr great risk reward trade
number ipr win could give
investor confid need
buy
think win ipr
what next potenti valu
sourc includ limit pubm wolf research
ultim main thing
concern us
compani diversifi
away key franchis
well face sig ip
consensu probabl model
franchis wrong
signific amount
revenu still come
consensu model dont includ sig chang
compani bd result overlap
indic drug small market
addit competit uncertainti lead sig
tv issu mani model
even though switch
pnh pt ultomiri consensu
model eros vs
consensu revenu
year given expect soliri eros
consensu model impact margin
look compet pnh
control ivh
fcrn competit signific mg think
like play big role
competit threat hurt price
put pressur new pt captur
sourc includ limit pubm wolf research
issu hasnt diversifi away
ipr key
soliri patent
us
failur pivot
busi key
ipr like determin
biosimilar soliri entri
earli signific
compani key franchis
sig pressur come
competit biosimilar
date mgt bd deal done
littl diversifi away
sourc includ limit pubm wolf research
remind challeng alxn
patent mean ipr differ loe
pnh/ahu
note soliri also protect orphan drug exclus treat gmg
nmosd
composit
composit
method use
method use
method use
antibodi
treatment inflammatori diseas
treatment pnh patient
inhibitor complement
treatment pnh patient
inhibitor complement
treatment pnh patient
inhibitor complement
treatment pnh patient
inhibitor complement
method composit treat
uspto
sourc includ limit pubm wolf research
ipr institut saw
stock sell final decis expect aug
sourc includ limit pubm wolf research
given alxn revenu still come
ipr decis could sig effect top-lin
year consensu still see rev come franchis
sourc includ limit pubm wolf research
addit alxn pipelin underwhelm
expans mostli overlap market
preclin earli tell
sourc includ limit pubm wolf research
combin w/ signific incom
con estimate revenu
sourc includ limit pubm wolf research
well high list price product
see franchis may
sourc includ limit pubm wolf research
creat sig revenue uncertainti year make
termin valu much riskier year dcf model
keep mind
deriv alter base case
model reflect shorter valuat time frame
base case valuat model
dcf enterpris valu
sourc includ limit pubm wolf research
issu think error
compani diversifi
away key franchis
well face sig ip
consensu probabl model
franchis wrong
signific amount
revenu still come
consensu model dont includ sig chang
compani bd result overlap
indic drug small market
addit competit uncertainti lead sig
tv issu mani model
even though switch
pnh pt ultomiri consensu
model eros vs
consensu revenu
year given expect soliri eros
consensu model impact margin
look compet pnh
control ivh
fcrn competit signific mg think
like play big role
competit threat hurt price
put pressur new pt captur
sourc includ limit pubm wolf research
start w/ switch management slide indic pnh switch
end w/ intent switch
sourc includ limit pubm wolf research
yet consensu model soliri pnh
eros total soliri eros
keep mind despit soliri pnh convers aspir soliri convers
indic consensu model pnh eros total eros
sourc includ limit pubm wolf research
w/ ultomiri move conveni
cheaper see littl incent new pt start soliri
illustr right
show hypothet soliri vs ultomiri dose
addit ultomiri infus time lower soliri
minut
time frame estimate total infus time hr
ultomiri vs hr soliri
ultomiri discount soliri
sourc includ limit pubm wolf research
given sig competit pressur
see total soliri erod
competit entri
sourc includ limit pubm wolf research
secondli consensu littl chang
compani margin move forward
sourc includ limit pubm wolf research
w/ lower price ultomiri on-going gmg/nmo
launch see room /- oper leverag
bull/bear scenario later
sourc includ limit pubm wolf research
lastli import call eu soliri
patent came biosimilar enter approv
eu orphan drug exclus pnh expir
supplementari protect
certif eu associ w/ comp
matter patent countri
patent relat pharmaceut
composit soliri pnh soliri
composit matter
sourc includ limit pubm wolf research
havent seen biosimilar eu yet
class good uptak soliri biosimilar
russia done well
sourc includ limit pubm wolf research
howev dilig suggest closest
biosimilar market amgn/sb would enter late
earliest
earn call
disclos trial still
given ldh endpoint even
trial enrol fulli end full
result would known end
assum month filling/fda review
given actual studi start date
trial month
assum samsung bioepi track
sourc includ limit pubm wolf research
indic pnh odd
possibl off-label use
could make eu headwind
sourc includ limit pubm wolf research
issu upcom brand competit
franchis legit
compani diversifi
away key franchis
well face sig ip
consensu probabl model
franchis wrong
signific amount
revenu still come
consensu model dont includ sig chang
compani bd result overlap
indic drug small market
addit competit uncertainti lead sig
tv issu mani model
even though switch
pnh pt ultomiri consensu
model eros vs
consensu revenu
year given expect soliri eros
consensu model impact margin
look compet pnh
control ivh
fcrn competit signific mg think
like play big role
competit threat hurt price
put pressur new pt captur
sourc includ limit pubm wolf research
start lot program
target indic serv
highlight
sourc includ limit pubm wolf research
target stop intravascular
extravascular hemolysi contribut pnh
intravascular hemolysi red blood cell lysi
circul due mediat
intravascular hemolysi reb blood cell tag
opson macrophag spleen liver
bone marrow
soliri pt either dont get hb level
partial respond could util
sourc includ limit pubm wolf research
show superior soliri trial
primari endpoint baselin hb level saw
favor trend key secondari endpoint
given pt show increas
hb week vs decreas soliri pt
trend favor transfus avoid
secondari metric
sourc includ limit pubm wolf research
question mani pt
clinic meaning note pt
sourc note mediat
sourc includ limit pubm wolf research
nvss factor drug current
advanc indic
sourc includ limit pubm wolf research
far earli data pnh promis
serv somewhat poc target
given nvss program focu one track
move rapidli lnp
mention team work togeth move
asset asset forward four indic parallel
use interim analysi acceler
phase studi goal realli even better
slide goal alway
better slide think
case data readout realli make
think import thing note respect
pnh health author recogn unmet
need substanti patient
accept singl phase registr studi pnh
lnp excit feedback
gotten would like stop go
look addit indic build
patient pollut indic lnp move
sourc includ limit pubm wolf research
want highlight fcrn class could
competit indic like mg driven pathogen igg
auto-immun diseas mg mediat auto-antibodi complement system
inhibitor anti-fcrn could effect
prevent fcrn
degrad
lysosom elimin
bodi
soliri inhibit cleavag inhibit
deploy termin complement system includ
format membran attack complex
sourc includ limit pubm wolf research
sever anti-fcrn clinic develop think
one promis
adcc knockout
abdeg mutat
effector
function fcr
effector
function fcr
detail releas
on-going mg
itp
pv
on-going
mg itp
cidp
on-going
mg
on-going
mg hfdn
waiha
on-going mg
waiha go
in-
review
see
sourc includ limit pubm wolf research
data soliri mg look similar
argx could differenti lower cost posit earlier mg pt
annual cost mg tx
due cost clinic trial popul soliri restrict
refractori mg pt
argx posit earlier non-refractori mg pt
price cheaper soliri could decreas
sourc includ limit pubm wolf research
addit optimist adapt mg
trial that read
adapt trial design primari endpoint account durabl
dose weekli dose week week off-drug week
primari endpoint mg-adl respons achr pt week mg-adl respons defin point mg-adl drop
baselin least consecut week time within initi tx cycl
estimate pbo respons could
tx arm could show respons
dont think argx baselin isa imbal
argx primari endpoint build durabl
respons control pbo rate
show mg-adl respons wk
inclus sever mg pt could also
believ week drug week
drug dose regimen could suffici
could show efficaci that line
trial mg-adl respons
sourc includ limit pubm wolf research
scenario analysi suggest argx adapt trial could
like read stat sig howev still unclear fda requir
argx hit mg-adl drop
respons borderlin stat
sig due low
base case worst-cas scenario
trial could still read stat sig
assumpt base/worst case achr- pt dropout rate
notabl use fischer exact test calc argx use stat test may use
chi-squar test w/ larger popul sensit could give wiggl room
howev unclear fda think argx hit respond analysi miss mg-adl drop
sourc includ limit pubm wolf research
addit done anti-fcrn deal affibodi
program cut develop w/ still on-going
statu develop waiha mg subq
one via syntimmun acquisit
initi higher concentr formul
subcutan healthi volunt began decemb
reiniti phase ii program iv
formul hemolyt anemia quarterwith regard
myasthenia gravi may need addit dose-
rang up-front would seamless phase ii/iii type
trial
 john orloff evp
statu longer develop
good exampl affibodi transact paid
million up-front run sort phase
realiz high-risk program bacteri
sequenc involv therefor high risk
immunogen recent look phase data
affibodi base preliminari data think
may program move forward
sourc includ limit pubm wolf research
overal arent optimist chanc
main reason
efficaci data isnt good
argx igg drop
clinic set pv
effector-
relat
subq may
limit weekli dose
b/c full length mab
sourc includ limit pubm wolf research
thu model risk adj
sourc includ limit pubm wolf research
lastli want touch ra pharma drug
zilocoplan self-administ subq look
diversifi conveni
sourc includ limit pubm wolf research
call argx fcrn deep dive continu
believ zilocoplan real competitor soliri mg
tx arm
pt gmg
pt achr-ab posit gmg whove
pt achr-ab posit gmg
design
iv dose
week f/u pbo-
iv thereaft
mainten week pbo-control
zilocuplan zilocuplan
subq qday week long term-
tx arm
ist tx arm compar pbo
soc balanc pbo
soc balanc pbo
adl qmg assess day
primari endpoint mg-adl chang
baselin week measur worst-rank
primari endpoint qmg chang baselin
week
secondari endpoint mg-adl chang
baselin week
argx rarx compani present howard et al
sourc includ limit pubm wolf research
ra posit zilocoplan use outsid
refractori gmg pt thu potenti ahead
soliri data come
zilocoplan trial criteria requir
pt first fail tx ist unlik soliri trial
sourc includ limit pubm wolf research
bad lot good
especi current valuat
hasnt diversifi face
major busi
uncertainti price competit
consensu probabl model
competit legit
lot bad alreadi bake
pnh isnt big go forward
bake modest gmg growth
trade cheap
valuat vs takeout
soliris/ultomiri switch set
success
ultomiri advantag price
conveni
biosimilar adopt could limit
even bear case upsid
think mg hit
current level
comp analysi larg cap
ipr great risk reward trade
number ipr win could give
investor confid need
buy
think win ipr
what next potenti valu
sourc includ limit pubm wolf research
here thing new investor pay attent
lot bad alreadi bake
 target upsid
switch set success
pnh crowd market model
flat declin go forward
base case doesnt grow mg much
bake sig fcrn biosimilar penetr
larg cap biotech stock taken
trade similar rang price-to-earnings
ev/ebitda co taken
ultomiri built price defens price
cheaper soliri
ultomiri also conveni
dose attract pt
even bear case upsid
bear case still upsid current
level higher yield
sourc includ limit pubm wolf research
start lot bad alreadi bake
must
believ
stock
lose ipr biosimilar
enter get label use protect
indic gmg nmo
fcrn take substanti amount market share
ultim shrink refractori mg market
ultomiri price declin significantli time due
ad competit threat
compani get close us neuro
goal
given eu patent decis signific
biosimilar eros pnh label use
sourc includ limit pubm wolf research
bake lot base case alreadi price
declin indic geographi
sourc includ limit pubm wolf research
given competit come pnh
give biosimilar bx competit
keep mind model pnh growth driver fact peak
model eros base case model
sourc includ limit pubm wolf research
done fcrn mg alloc
new start biosimilar entri
sourc includ limit pubm wolf research
gener model biosimilar uptak
new patient start across geographi lead
keep mind
eu highest uptak given earliest entri rememb ema invalid patent
gener biosimilar enter market assum get new pt start
sourc includ limit pubm wolf research
move second point feel
takeout upsid esp win ipr
lot bad alreadi bake
 target upsid
switch set success
pnh crowd market model
flat declin go forward
base case doesnt grow mg much
bake sig fcrn biosimilar penetr
larg cap biotech stock taken
trade similar rang price-to-earnings
ev/ebitda co taken
ultomiri built price defens price
cheaper soliri
ultomiri also conveni week
dose attract pt
even bear case upsid
bear case still upsid current
level higher yield
sourc includ limit pubm wolf research
larg cap takeout yield premium
last yr w/ sig yield may
attract target
sourc includ limit pubm wolf research
deal premium rel previou close unless state otherwis
kicker current trade
rang co pre-takeout
ratio ltm month acquisit compar compani
factset calcul ratio wr calcul
sourc includ limit pubm wolf research
third think soliri ultomiri switch
success
lot bad alreadi bake
 target upsid
switch set success
pnh crowd market model
flat declin go forward
base case doesnt grow mg much
bake sig fcrn biosimilar penetr
larg cap biotech stock taken
trade similar rang price-to-earnings
ev/ebitda co taken
ultomiri built price defens price
cheaper soliri
ultomiri also conveni week
dose attract pt
even bear case upsid
bear case still upsid current
level higher yield
sourc includ limit pubm wolf research
thu model pt switch
next year
graph total pt count across pnh ahu gmg nmo geographi
sourc includ limit pubm wolf research
note earlier switch pitch like
receiv well pt ultomiri cheaper
illustr right
show hypothet soliri vs ultomiri dose
addit ultomiri infus time lower soliri
minut
time frame estimate total infus time hr
ultomiri vs hr soliri
ultomiri discount soliri
sourc includ limit pubm wolf research
less efficaci soliri
ahu studi adult
creatinin
sourc includ limit pubm wolf research
pnh tend show less breakthrough
hemolysi sub-optimal dose caus
due sub-optimal dose
due caus
sourc includ limit pubm wolf research
lastli think even bear case stock
upsid current level
lot bad alreadi bake
 target upsid
switch set success
pnh crowd market model
flat declin go forward
base case doesnt grow mg much
bake sig fcrn biosimilar penetr
larg cap biotech stock taken
trade similar rang price-to-earnings
ev/ebitda co taken
ultomiri built price defens price
cheaper soliri
ultomiri also conveni week
dose attract pt
even bear case upsid
bear case still upsid current
level higher yield
sourc includ limit pubm wolf research
recogn sig uncertainli around competit
threat price model scenario
sourc includ limit pubm wolf research
start use pricerx data dose
regimen calcul wa wac price
keep mind
took price rx data weight price increas intra-
quarter depend day effect
use estim annual average wac per indic
sourc includ limit pubm wolf research
use histor sale data disclosur
